Cardiovascular companies develop diagnostics, therapies and research technologies for diseases affecting the heart and circulatory system. Their work supports earlier detection, improved disease management and the development of new treatments for cardiovascular conditions.
This category includes companies working on:
Browse 71 UK cardiovascular companies below.
Oral and injectable peptide therapies for obesity and cardiometabolic disease
Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders. Its pipeline centres on rationally engineered peptide candidates acting on GLP-1 and amylin receptors, advanced through a proprietary oral absorption technology…
UK affiliate of global family-owned biopharmaceutical company
Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates…
Microbiome modulator ingredients for metabolic health and disease prevention
OptiBiotix Health is a biotechnology company developing and licensing microbiome modulator products for use in food ingredients, dietary supplements, and nutraceuticals. Its portfolio includes patented prebiotic and probiotic formulations targeting weight management, cholesterol reduction, cardiovascular health, and…
Genetically diverse iPSC models and high-throughput drug screening
Cytochroma is an Edinburgh biotechnology company producing genetically diverse human induced pluripotent stem cell-derived models for drug discovery and safety research. Its donor-matched panels include hepatocytes, cardiomyocytes and supporting cell types, enabling assessment of drug responses across different…
AI-driven neural data platform for bioelectronic medicine
BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve activity to physiological conditions through the discovery of neural biomarkers, supporting the development of personalised neuromodulation…
Single-molecule counting point-of-care diagnostics for cardiac and other biomarkers
Psyros Diagnostics develops a point-of-care diagnostic system using single-molecule counting technology to measure biomarkers at extremely low concentrations within around ten minutes, from a single drop of blood. The platform's lead application is a high-sensitivity troponin assay for cardiac diagnosis, with the…
Specialist CRO for ion channel screening and cardiac safety assessment
Metrion Biosciences is a contract research organisation specialising in preclinical ion channel biology, cardiac safety screening, and neuroscience drug discovery services. Founded in 2015 as a spin-out from Xention Limited, Metrion provides automated and manual patch clamp electrophysiology, GLP-compliant hERG…
Platelet function biomarkers and assays for cardiovascular clinical research
HaemAnalytica is a University of Reading biotechnology spin-out developing platelet-function assays for cardiovascular research and clinical trials. Its TRIPLEcheck platform uses platelet biomarkers to predict thrombotic risk and antiplatelet treatment response. PLANA combines preserved blood samples, flow cytometry…
Coronary plaque biomarkers for precision cardiovascular medicine
PlaqueTec develops a catheter-based liquid biopsy system to investigate biological processes driving coronary artery disease. Its device samples blood at sites around coronary plaques, allowing researchers to compare local concentrations of proteins and other molecules. These data feed its BioCarta platform for…
Oral NLRP3 inhibitors for cardiovascular and neurologic inflammation
Rezera, formerly NodThera, is a clinical-stage biotechnology company developing small molecule inhibitors of NLRP3, an inflammasome implicated in chronic inflammatory and neurodegenerative disease. Its lead asset, ruvonoflast, is a brain-penetrant oral inhibitor that has completed Phase II trials and is advancing…
Novel small-molecule anti-fibrinolytic for acute traumatic and surgical bleeding
ClotProtect Therapeutics is a University of Leeds spin-out developing a first-in-class small molecule anti-fibrinolytic to address acute bleeding following trauma and surgery. The company's approach directly inhibits the enzyme responsible for blood clot breakdown, aiming to offer greater efficacy than current…
Global licensing and commercialisation of established branded pharmaceutical medicines
Pharmanovia is a specialty pharmaceutical company that acquires, licenses and commercialises established branded medicines, extending their lifecycle for patients worldwide. The company's portfolio spans more than 25 medicines across endocrinology, neurology, cardiovascular and oncology, built through strategic…
Perfluorocarbon oxygen carrier therapeutic and MRI imaging agent for acute stroke
Aurum Biosciences is a Scottish clinical-stage biopharmaceutical company developing ABL-101, a perfluorocarbon-based oxygen carrier that bypasses arterial clots to deliver oxygen to ischaemic tissue via collateral vessels. The lead indication is acute ischaemic stroke, with ABL-101 having completed Phase 1 and 2a…
Cell-based regenerative therapies for heart failure
Cardiogeni is a clinical-stage biotechnology group developing regenerative cell medicines for cardiovascular disease. Its lead programme, CLXR-001, uses engineered immunomodulatory progenitor cells intended to support repair of damaged heart tissue in patients with heart failure. The group is progressing plans for…
RNA sequencing liquid biopsy for cardiovascular and complex disease screening
MultiplAI Health is a Cambridge biotech developing a whole-blood RNA sequencing test for early screening of cardiovascular and other complex diseases. Its platform combines transcriptomic profiling of blood samples with a patented data transformation process and proprietary deep learning algorithms to generate…
Single-pill fixed-dose combinations for cardiometabolic disease
George Medicines is a late-stage biopharmaceutical company developing innovative single-pill, fixed-dose combination therapies for cardiometabolic diseases. Rather than pursuing early drug discovery, the company reformulates established best-in-class small molecules into novel proprietary low-dose combinations…
Europe's largest biomedical discovery institute researching the biology of disease
The Francis Crick Institute is a biomedical discovery institute researching the biology underlying human health and disease. The Institute studies biology from molecules to entire organisms, translating discoveries into new ways to treat illnesses including cancer, heart disease and neurodegenerative conditions.…
Blood-based liquid biopsy for endothelial glycocalyx and microvascular health
Dimension Biotechnologies is a biotech developing a rapid, blood-based diagnostic for microvascular health based on analysis of the endothelial glycocalyx, the molecular layer lining blood vessel walls whose biochemical integrity is disrupted early in cardiovascular disease, kidney disease, diabetes, and sepsis. The…
Isoform-specific antibody therapeutics for vascular disease
IsomAb is a biotechnology company developing isoform-specific antibody therapeutics for serious vascular diseases. Its lead programme, ISM-001, targets VEGF-A165b, an anti-angiogenic splice isoform implicated in peripheral arterial disease and chronic limb-threatening ischaemia. The company uses a…
Human iPSC-derived disease models and drug discovery services
Axol Bioscience is a biotechnology company supplying human induced pluripotent stem cell-derived cells and research services for disease modelling and drug discovery. Its portfolio includes neurons, cardiomyocytes, retinal organoids, retinal pigment epithelium and skin cell models, alongside culture media and custom…